Back HIV/AIDS HIV/AIDS Topics HIV Treatment

European Commission Approves Boosted Darunavir Combo Rezolsta for HIV

The European Commission last month approved a new fixed-dose coformulation -- dubbed Rezolsta -- containing the HIV protease inhibitor darunavir boosted with the novel pharmacoenhancer cobicistat, Janssen recently announced. The combination is currently being evaluated for U.S. approval.

alt

Read more:

Only 30% of People with HIV in U.S. Have Undetectable Viral Load

Less than one-third of people living with HIV in the U.S. are on antiretroviral therapy (ART) with full viral suppression, which is key to good health and reduced risk of transmission, according to the latest CDC Vital Signs report. In 2011, out of an estimated 1.2 million people living with HIV, just 4 in 10 were receiving HIV medical care and only 3 in 10 had undetectable viral load. "The bottom line is HIV care and treatment not only work to improve health and prolong lives, but also prevent transmission," said CDC director Tom Frieden. "You can save your life and save the life of someone else."

alt

Read more:

Delaying Treatment More than 12 Months after HIV Infection Reduces CD4 Cell Recovery

People with HIV who start antiretroviral therapy (ART) more than a year after seroconversion have a lower likelihood of regaining normal CD4 T-cell counts, researchers reported in the November 24 online edition of JAMA Internal Medicine. "If full restoration of immunologic and clinical health is our goal, then the present study tells us that the best chance we have is to start antiretroviral therapy within 12 months of infection," according to an accompanying editorial.

alt

Read more:

December 1 Is World AIDS Day

Monday, December 1, is the 26th World AIDS Day, an opportunity both to remember the millions of people who have been lost to the epidemic and to raise awareness and focus efforts on ongoing challenges such as gaps in HIV prevention and care. An estimated 1.2 million people in the U.S. and 35 million worldwide are now living with HIV/AIDS, according to the CDC.

alt

Read more:

Complete Coverage of HIV Drug Therapy 2014

HIVandHepatitis.com coverage of the HIV Drug Therapy 2014 Conference Research, November 2-6, 2014, in Glasgow, Scotland.

Full listing of coverage by topic

HIV Drug Therapy 2014 website

11/4/14

alt

HIV R4P: Positive Response to Gift Tokens for Undetectable Viral Load Trial

A U.S. study presented at last month’s HIV Research for Prevention conference found generally positive responses among people with HIV and clinic staff to a trial that used $70 gift tokens as an incentive for people to maintain an undetectable viral load. However, the study found that only just under half of patients had an accurate understanding of what viral load was, and that this did not improve during the study.

alt

Read more:

HIV Drug Therapy: Once-daily Dolutegravir Superior to Darunavir at 96 Weeks

Treatment with a triple antiretroviral combination containing the once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported this month at the HIV Drug Therapy Glasgow conference.

alt

Read more: